Q4 2022 Results
Company overview
Innovation: Pipeline overview
Cardiovascular
Financial review
Immunology
2023 priorities
Innovation: Clinical trials
Neuroscience
pelacarsen - Antisense oligonucleotide (ASO)
targeting Lp(a)
NCT04023552 Lp(a)HORIZON (CTQJ230A12301)
Indication
Phase
Patients
Primary
Outcome
Measures
Arms
Intervention
Target
Patients
Secondary prevention of cardiovascular events in patients with elevated levels
of lipoprotein(a)
Phase 3
8323
Time to the first occurrence of MACE (cardiovascular death, non-fatal MI, non-
fatal stroke and urgent coronary re-vascularization)
TQJ230 80 mg injected monthly subcutaneously or matched placebo
Patients with a history of Myocardial infarction or Ischemic Stroke, or a clinically
significant symptomatic Peripheral Artery Disease, and Lp(a) ≥ 70 mg/dL
Readout
Milestone(s)
2025
Publication
TBD
66 Investor Relations | Q4 2022 Results
Oncology
Appendix
Abbreviations
Other
NOVARTIS | Reimagining MedicineView entire presentation